Volume 5, Number 5—October 1999
Research
Abscesses due to Mycobacterium abscessus Linked to Injection of Unapproved Alternative Medication
Table
Patient and treatment characteristics | Persons with abscesses (n = 87) | Persons without abscesses (n = 42) |
---|---|---|
Median age | 45 years | 46 years |
(Range) | (15-74) | (20-77) |
Sex | ||
Female | 81 (93%) | 35 (83%) |
Male | 6 (7%) | 7 (17%) |
Median dose | 1 cc | 1 cc |
(Range) | (1-2 cc) | (1-10 cc) |
Dose frequency | ||
Single | 35 (40%) | 11 (26%) |
Monthly | 25 (29%) | 10 (24%) |
Source of injection | ||
Provider | 77 (89%) | 34 (81%) |
Self/home | 9 (10%) | 8 (19%) |
Both | 1 (1%) | |
Primary route of administration | ||
Intramuscular | 86 (99%) | 36 (86%) |
Intravenous | 1 (1%) | 6 (14%) |
Intramuscular site | ||
Gluteal | 82 (95%) | 29 (69%) |
Other | 4 (5%) | 13 (31%) |
Indicationa | ||
Weight loss | 61 (70%) | 23 (55%) |
Fatigue | 11 (13%) | 9 (21%) |
Hypoadrenalism | 9 (10%) | 10 (24%) |
Other | 13 (15%) | 8 (19%) |
aSome persons received ACE* for more than one indication.
Page created: December 15, 2010
Page updated: December 15, 2010
Page reviewed: December 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.